Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at $55,285,726.65. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Helen Torley also recently made the following trade(s):

• On Friday, October 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $74.44, for a total value of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $68.98 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $79.50. The stock’s 50 day moving average price is $70.45 and its 200-day moving average price is $61.97. The company has a market capitalization of $8.07 billion, a PE ratio of 15.78, a PEG ratio of 0.40 and a beta of 1.16. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the previous year, the business earned $0.91 EPS. The company’s revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Preservation Advisors LLC bought a new stake in Halozyme Therapeutics during the 1st quarter valued at $32,000. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $32,000. SVB Wealth LLC bought a new stake in Halozyme Therapeutics during the 1st quarter valued at $33,000. Bessemer Group Inc. raised its holdings in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 207 shares during the period. Finally, Employees Retirement System of Texas bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $34,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Halozyme Therapeutics in a report on Saturday, September 27th. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 2nd. Benchmark lifted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $70.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.